文献速递其他结缔组织病系统性红斑狼疮

西罗莫司治疗难治性结缔组织病相关血小板减少症患者的初步研究

Sirolimus for the treatment of patients with refractory connective tissue disease-related thrombocytopenia: a pilot study.
PubMed 文献 · Rheumatology (Oxford) · 2024-01-01

这项单臂、开放标签、初步研究纳入12例对常规药物无效或不耐受的结缔组织病相关免疫性血小板减少症(CTD-ITP)患者,口服西罗莫司6个月,起始剂量0.5-1 mg/日,调整至血药浓度6-15 ng/ml。6例(50%)达完全缓解,2例(16.7%)达部分缓解,4例(33.3%)无缓解;未观察到严重药物相关毒性。作者认为结果支持西罗莫司作为难治性CTD-ITP的替代方案。

要点

  • 12例难治性CTD-ITP患者中6例(50%)完全缓解、2例(16.7%)部分缓解、4例(33.3%)无缓解。
  • 4例原发性干燥综合征中3例、3例系统性红斑狼疮中2例达总体缓解。
  • 2例重叠干燥综合征与系统性红斑狼疮中1例在6个月时达完全缓解。

核心结论

  • 作者认为结果支持西罗莫司作为难治性CTD-ITP患者的替代方案,包括系统性红斑狼疮和原发性干燥综合征。

研究设计与样本

  • 单臂、开放标签、初步研究,纳入对常规药物无效或不耐受的CTD-ITP患者。
  • 2020年11月至2022年2月连续入组12例住院患者并进行前瞻性随访。
  • 患者口服西罗莫司6个月,起始剂量0.5-1 mg/日,根据耐受性和维持血药浓度6-15 ng/ml调整剂量。
  • 主要疗效终点为血小板计数变化,总体缓解按ITP国际工作组标准评估。

主要发现

  • 12例患者中6例(50%)达完全缓解,2例(16.7%)达部分缓解,4例(33.3%)无缓解。
  • 4例原发性干燥综合征患者中3例达总体缓解,3例系统性红斑狼疮患者中2例达总体缓解。
  • 2例重叠干燥综合征与系统性红斑狼疮患者中1例在6个月时达完全缓解。
  • 未观察到严重药物相关毒性。

关键数值与推荐

  • 总体缓解按ITP国际工作组标准评估。
  • 西罗莫司起始剂量0.5-1 mg/日,调整至血药浓度6-15 ng/ml。

临床怎么用

  • 作者认为西罗莫司可作为难治性CTD-ITP患者的替代方案,包括系统性红斑狼疮和原发性干燥综合征。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: CTD-related immune thrombocytopenia (CTD-ITP) represents an unmet medical need because the drugs that are available are only partly effective and have considerable side-effects. The aim of this study was to assess the efficacy and safety of sirolimus in refractory CTD-ITP patients. METHODS: We did a single-arm, open-label, pilot study of sirolimus in patients with CTD-ITP unresponsive to, or intolerant of, conventional medications. Patients received oral sirolimus for 6 months at a starting dose of 0.5-1 mg per day, with dose adjusted according to tolerance and to maintain a therapeutic range of 6-15 ng/ml. The primary efficacy end point was changes in platelet count, and overall response assessed according to the ITP International Working Group Criteria. Safety outcomes included tolerance as assessed by the occurrence of common side-effects. RESULTS: Between November 2020 and February 2022, 12 consecutively hospitalized patients with refractory CTD-ITP were enrolled and prospectively followed. Of these, six patients (50%) achieved complete response, two (16.7%) achieved partial response, and four (33.3%) were no response under therapy. Three of four patients with primary Sjögren's syndrome and two of three patients with systemic lupus erythematosus achieved overall response. One of two patients with overlapping Sjögren's syndrome and systemic lupus erythematosus achieved complete response at 6 months. No severe drug-related toxicities were observed. CONCLUSION: Our results do support sirolimus as an alternative regimen for refractory CTD-ITP patients, including systemic lupus erythematosus and primary SS.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Du H, Su W, Su J, et al. Sirolimus for the treatment of patients with refractory connective tissue disease-related thrombocytopenia: a pilot study. Rheumatology (Oxford). 2024. PMID: 37079730. doi:10.1093/rheumatology/kead160

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。